Literature DB >> 26374072

CCR 20th Anniversary Commentary: Simpson's Paradox and Neoadjuvant Trials.

Lisa A Carey1.   

Abstract

The research article by Carey and colleagues, published in the April 15, 2007, issue of Clinical Cancer Research, described the relationship between response to neoadjuvant chemotherapy and outcome by tumor subtype. Today neoadjuvant clinical trials are often designed to provide correlative data to help identify predictive biomarkers or to focus on poor-risk patients identified by residual disease after neoadjuvant treatment. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26374072      PMCID： PMC4573539          DOI： 10.1158/1078-0432.CCR-14-3124

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  21 in total

1.  Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

Authors:  Justin M Balko; Jennifer M Giltnane; Kai Wang; Luis J Schwarz; Christian D Young; Rebecca S Cook; Phillip Owens; Melinda E Sanders; Maria G Kuba; Violeta Sánchez; Richard Kurupi; Preston D Moore; Joseph A Pinto; Franco D Doimi; Henry Gómez; Dai Horiuchi; Andrei Goga; Brian D Lehmann; Joshua A Bauer; Jennifer A Pietenpol; Jeffrey S Ross; Gary A Palmer; Roman Yelensky; Maureen Cronin; Vincent A Miller; Phillip J Stephens; Carlos L Arteaga
Journal:  Cancer Discov       Date:  2013-12-19       Impact factor: 39.397

2.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Authors:  S Loi; S Michiels; R Salgado; N Sirtaine; V Jose; D Fumagalli; P-L Kellokumpu-Lehtinen; P Bono; V Kataja; C Desmedt; M J Piccart; S Loibl; C Denkert; M J Smyth; H Joensuu; C Sotiriou
Journal:  Ann Oncol       Date:  2014-03-07       Impact factor: 32.976

3.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Authors:  Gunter von Minckwitz; Andreas Schneeweiss; Sibylle Loibl; Christoph Salat; Carsten Denkert; Mahdi Rezai; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Dirk M Zahm; Sherko Kümmel; Holger Eidtmann; Peter Klare; Jens Huober; Serban Costa; Hans Tesch; Claus Hanusch; Jörn Hilfrich; Fariba Khandan; Peter A Fasching; Bruno V Sinn; Knut Engels; Keyur Mehta; Valentina Nekljudova; Michael Untch
Journal:  Lancet Oncol       Date:  2014-04-30       Impact factor: 41.316

4.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

Authors:  Carsten Denkert; Gunter von Minckwitz; Jan C Brase; Bruno V Sinn; Stephan Gade; Ralf Kronenwett; Berit M Pfitzner; Christoph Salat; Sherene Loi; Wolfgang D Schmitt; Christian Schem; Karin Fisch; Silvia Darb-Esfahani; Keyur Mehta; Christos Sotiriou; Stephan Wienert; Peter Klare; Fabrice André; Frederick Klauschen; Jens-Uwe Blohmer; Kristin Krappmann; Marcus Schmidt; Hans Tesch; Sherko Kümmel; Peter Sinn; Christian Jackisch; Manfred Dietel; Toralf Reimer; Michael Untch; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2014-12-22       Impact factor: 44.544

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 6.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321

7.  Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Authors:  William M Sikov; Donald A Berry; Charles M Perou; Baljit Singh; Constance T Cirrincione; Sara M Tolaney; Charles S Kuzma; Timothy J Pluard; George Somlo; Elisa R Port; Mehra Golshan; Jennifer R Bellon; Deborah Collyar; Olwen M Hahn; Lisa A Carey; Clifford A Hudis; Eric P Winer
Journal:  J Clin Oncol       Date:  2014-08-04       Impact factor: 44.544

8.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

Authors:  Sherene Loi; Nicolas Sirtaine; Fanny Piette; Roberto Salgado; Giuseppe Viale; Françoise Van Eenoo; Ghizlane Rouas; Prudence Francis; John P A Crown; Erika Hitre; Evandro de Azambuja; Emmanuel Quinaux; Angelo Di Leo; Stefan Michiels; Martine J Piccart; Christos Sotiriou
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

9.  Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

Authors:  David Cameron; Julia Brown; Rebecca Dent; Christian Jackisch; John Mackey; Xavier Pivot; Guenther G Steger; Thomas M Suter; Masakazu Toi; Mahesh Parmar; Rita Laeufle; Young-Hyuck Im; Gilles Romieu; Vernon Harvey; Oleg Lipatov; Tadeusz Pienkowski; Paul Cottu; Arlene Chan; Seock-Ah Im; Peter S Hall; Lida Bubuteishvili-Pacaud; Volkmar Henschel; Regula J Deurloo; Celine Pallaud; Richard Bell
Journal:  Lancet Oncol       Date:  2013-08-07       Impact factor: 41.316

10.  Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.

Authors:  Aleix Prat; Lisa A Carey; Barbara Adamo; Maria Vidal; Josep Tabernero; Javier Cortés; Joel S Parker; Charles M Perou; José Baselga
Journal:  J Natl Cancer Inst       Date:  2014-08-19       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.